The US Food and Drug Administration has approved the RNA interference drug givosiran (Alnylam Pharmaceuticals' Givlaari) to treat acute hepatic porphyria in adults, according to the agency.
The US Food and Drug Administration has approved the RNA interference drug givosiran (Alnylam Pharmaceuticals' Givlaari) to treat acute hepatic porphyria in adults, according to the agency.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.